[8-K] DuPont de Nemours, Inc. Reports Material Event

Rhea-AI Filing Summary

DuPont announced a definitive agreement to sell its Aramids business (Kevlar4 and Nomex4) to Arclin for an enterprise value of approximately $1.8 billion. Under the Transaction Agreement, DuPont will receive roughly $1.2 billion in pre-tax cash at closing (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at $325 million, expected to represent about a 17.5% ownership at closing. The agreement is conditioned on customary closing requirements, including regulatory approvals in multiple non-U.S. jurisdictions and satisfactory representations, warranties and performance by the parties.

Positive

• $1.2 billion in expected pre-tax cash proceeds at closing provides near-term liquidity
• Retention of a non-controlling equity interest (~17.5%, valued at $325 million) allows participation in potential future upside
• Deal value of approximately $1.8 billion monetizes the Aramids business

Negative

• A $300 million note receivable and equity stake mean part of consideration is not immediate cash
• Completion is conditioned on regulatory approvals in multiple non-U.S. jurisdictions, which could delay or impact closing
• Proceeds are subject to customary transaction adjustments, so final amounts may differ from initial estimates

Insights

Financial Analyst

TL;DR: DuPont is monetizing its Aramids unit for cash, a note, and equity, crystallizing value while retaining a minority stake.

The deal structure splits consideration into immediate liquidity ($1.2 billion pre-tax cash), a material $300 million note receivable, and an equity interest ($325 million, ~17.5% expected stake). This combination delivers near-term proceeds and potential upside through retained equity exposure. The filing highlights standard closing conditions and cross-border regulatory approvals, which are typical and may extend timing. The agreement ties certain obligations to the accuracy of representations and material performance by each party.

M&A Specialist

TL;DR: Transaction is a structured divestiture with mixed consideration and customary closing conditions, including multi-jurisdictional regulatory clearances.

The purchase consideration mix—cash, a promissory note, and non-controlling equity—is consistent with transactions balancing immediate proceeds and continued upside participation. The documented requirement for regulatory approvals across several non-U.S. jurisdictions and standard representation and warranty conditions signals typical execution risk but no unusual concessions are disclosed in the provided text. Timing and final proceeds could change due to customary adjustments noted in the agreement.

false 0001666700 0001666700 2025-08-29 2025-08-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025 (August 29, 2025)

DuPont de Nemours, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38196		81-1224539
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

974 Centre Road, Building 730 Wilmington, DE		19805
(Address of principal executive offices)		(Zip Code)

(302) 295-5783

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		DD		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On August 29, 2025, DuPont de Nemours, Inc., a Delaware corporation (the “Company” or “DuPont”) entered into a Transaction Agreement (the “Transaction Agreement”) with ARC Falcon Holdings, L.P., a Delaware limited partnership (“Holdings”), and New Arclin U.S. Holding Corp., a Delaware corporation and wholly-owned subsidiary of Holdings (“Buyer”, and together with Holdings and their subsidiaries, “Arclin”), pursuant to which, subject to the satisfaction of customary closing conditions set forth in the Transaction Agreement, DuPont has agreed to sell to Arclin the Company’s Aramids business (Kevlar^® and Nomex^®) in a transaction valuing the business at approximately $1.8 billion (the “Transaction”). At the closing of the Transaction, DuPont will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million, which is expected to represent an approximate 17.5% stake at the time of the closing.

Consummation of the Transaction is subject to the satisfaction or waiver of certain customary mutual closing conditions, including (i) the absence of an injunction in certain agreed jurisdictions that would prohibit consummation of the Transaction and (ii) the expiration or termination of the required waiting, notice or review periods and approvals or clearances under the Hart-Scott-Rodino Act, as amended, and certain other approvals under non-U.S. regulatory laws, as applicable, including, without limitation, the European Union, Japan, China, South Korea and the United Kingdom. The obligation of each party to consummate the Transaction is also conditioned upon the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Transaction Agreement.

The Transaction Agreement contains representations, warranties and covenants of the Company, Holdings and Buyer generally customary for a transaction of this type. The Transaction Agreement also provides for customary indemnification related to liabilities intended to be assumed by Buyer or retained by Company and other matters. The Company and Buyer also agreed to use their reasonable best efforts to cause the Transaction to be consummated and to obtain any required regulatory approvals.

The Transaction Agreement contains certain termination rights, including, among others, (i) for the Company and Buyer, if the Transaction is not consummated on or before May 1, 2026, subject to two extensions of two months each if all closing conditions have been satisfied other than those related to the receipt of regulatory approvals and those to be satisfied at closing, and (ii) for the Company and Buyer, if, in the case of the Company, any of Holdings’ or Buyer’s representations and warranties fails to be true and correct or Holdings or Buyer breaches or fails to perform its covenants or other agreements or, in the case of Buyer, any of the Company’s representations and warranties fails to be true and correct or the Company breaches or fails to perform its covenants or other agreements, in each case, such that a closing condition fails to be satisfied.

The foregoing description of the Transaction Agreement is subject to, and qualified in its entirety by reference to, the full text of the Transaction Agreement, a copy of which is attached as Exhibit 2.1 hereto and is incorporated by reference herein. The Transaction Agreement has been attached to provide information regarding its terms. It is not intended to provide any other factual information about the Company, Holdings, Buyer, the business sold by the Company or the business of Holdings and Buyer under the Transaction Agreement. In particular, the assertions embodied in the representations and warranties in the Transaction Agreement were made as of a specified date, are modified or qualified by information in a confidential disclosure letter prepared in connection with the execution and delivery of the Transaction Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to stockholders, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Transaction Agreement are not necessarily characterizations of the actual state of facts about the Company, Holdings, Buyer, the business sold by the Company, or the business of Holdings and Buyer under the Transaction Agreement at the time they were made or otherwise and should only be read in conjunction with the other information that the Company, Holdings or Buyer make publicly available in reports, statements and other documents filed with the U.S. Securities and Exchange Commission.

2

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
2.1		Transaction Agreement by and among DuPont de Nemours, Inc., ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., dated August 29, 2025.*†
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Schedules (or similar attachments) have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules (or similar attachments) upon request by the U.S. Securities and Exchange Commission; provided that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules (or similar attachments) so furnished.

† Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

Cautionary Statement Regarding Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “see”, “will”, “would”, “target”, “outlook”, “stabilization”, “confident”, “preliminary”, “initial” and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements, including statements regarding outlook, expectations and guidance, including with respect to the potential impact of tariffs and discussion of trade sensitivity and macroeconomic uncertainties. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion (if at all), account and tax treatment of the proposed transaction including (x) any failure to obtain necessary regulatory approvals or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction, and (z) risks and costs and pursuit and/or implementation, timing and impacts to business operations of the separation of business lines in scope for the proposed transaction; (ii) the impact of the proposed transaction and ownership of a minority interest, estimated to be 17.5%, in the future Arclin company on DuPont’s results of operations; (iii) other risks to DuPont’s business and operations, including the risk of impairment; and (iv) other risk factors discussed in DuPont’s most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUPONT DE NEMOURS, INC.
By:		/s/ Erik T. Hoover
Name:		Erik T. Hoover
Title:		Senior Vice President and General Counsel

Date: September 2, 2025

4

FAQ

What business is DuPont selling in the 8-K (DD)?

DuPont is selling its Aramids business (Kevlar4 and Nomex4) to Arclin.

What is the reported transaction value for the Aramids sale?

The Transaction is valued at approximately $1.8 billion.

What consideration will DuPont receive at closing?

At closing DuPont will receive approximately $1.2 billion pre-tax cash, a $300 million note receivable, and a $325 million non-controlling equity interest (expected ~17.5%).

Are there conditions to completing the sale?

Yes. Closing is conditioned on customary conditions, including the accuracy of representations and warranties, performance by the parties, and regulatory approvals in several non-U.S. jurisdictions.

Will the final proceeds be exactly as stated?

No. The pre-tax cash proceeds are stated as approximately $1.2 billion and are subject to customary transaction adjustments, so final amounts may vary.